期刊文献+

脱氧氟尿苷脂质体的制备及其质量评价 被引量:1

Preparation and Quality Evaluation of Doxifluridine Liposomes
原文传递
导出
摘要 目的:优选脱氧氟尿苷脂质体的制备工艺及建立其质量评价方法。方法:采用逆相蒸发法制备脂质体,并以包封率为参考指标,以处方中卵磷脂与胆固醇摩尔比(A)、有机相与水相体积比(B)、脱氧氟尿苷浓度(C)、磷酸盐缓冲液pH值(D)为因素通过正交试验优选该脂质体的处方,并对脂质体粒径、包封率、稳定性、体外释药情况等进行考察。结果:最佳处方为A2:1、B5:1、C2mg.mL-1、D7.0。以此处方制备的脂质体平均粒径231nm,包封率(52.22±1.30)%,贮藏49d稳定性较好,与脱氧氟尿苷溶液比较具有明显的缓释性。结论:建立的脱氧氟尿苷脂质体制备方法简便、可行,以优选处方制备的脂质体质量符合要求。 OBJECTIVE: To optimize the preparation technology of doxifluridine (DFUR) liposomes and establish its quality evaluation method. METHODS: The DFUR liposomes were prepared by reverse phase evaporation technique using entrapment efficiency as index, the optimal formulation of liposomes was determined with mole ratio of lecithin to cholesterin (A), volume ratio of organic phase to water phase (B), DFUR concentration (C) and the pH of buffer phosphate (D) as factors, and the particle size, entrapment efficiency, stability and in vitro drug release were investigated as well. RESULTS: The optimal formulation was as follows: A was 2 : 1, B was 5 : 1, C was 2 mg · mL ^-1 and D was 7.0. Under this formulation, the mean diameter of the liposomes was 231 nm and the entrapment efficiency was (52.22 ± 1.30) %, and the liposomes were stable within 49 days and marked by sustained - release as compared with DFUR solution. CONCLUSION : The operation of prepa- ration is simple and feasible, and the optimized liposomes were up to the standard.
出处 《中国药房》 CAS CSCD 北大核心 2009年第31期2439-2441,共3页 China Pharmacy
基金 吉林大学“大学生创新性实验计划”资助项目(2008C73202)
关键词 脱氧氟尿苷 脂质体 制备 质量评价 包封率 Doxifluridine Liposomes Preparation Quality evaluation Entrapment efficiency
  • 相关文献

参考文献4

二级参考文献12

共引文献13

同被引文献12

  • 1王馨,黄华.醋酸泼尼松龙固体脂质纳米粒的试制[J].中国医药工业杂志,2007,38(7):499-501. 被引量:8
  • 2Lopez-Pinto JM, Gonzalez-Rodriguez ML, Rabasco AM. Effect of cholesterol and ethanol on dermal delivery from DPPC liposome[J], lnt J Pharm, 2005,298 ( 1 ) : 1.
  • 3Godin B, Touitou E. Mechanism of bacitracin permeation enhancement through the skin and cellular membranes from an ethosomal carrier[J].J Control Release, 2004,94 (2-3):365.
  • 4Nava D, Touitou E. Carriers for skin delivery of trihexy- phenidyl HCI: ethosomes vs. liposomes[J]. Biomaterials, 2000,21(18) : 1 879.
  • 5Touitou E, Dayan N, Bergelson L, et al. Ethosomes-nov- el vesicular carriers for enhanced delivery: Characteriza- tion and skin penetration properties[J]. J Control Release, 2000,65(3) :403.
  • 6Teeranachaideekul V, Souto EB, Junyaprasert VB, et al. Cetyl palmitate-based NLC for topical delivery of eoen- zyme Q10---Development, physicochemieal characteriza- tion and in vitro release studies[J]. Eur J Pharm Bio- pharm,2007,67(1) : 141.
  • 7Lu Q, Yu A, Xi Y, et al. Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical de- livery[J]. Int J Pharm, 2009,372 ( 1-2 ) : 191.
  • 8Sun W, Zhang N, Li A, et al. Preparation and evaluation of N3-O-toluyl-fluorouracil-loaded liposomes[J]. Int J Pharm, 2008,353(1-2) :243.
  • 9Morissettea SL, Almarsson O, Peterson ML, et al. High- throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids[J]. Adv Drug Deliv Rev, 2004,56(3) :275.
  • 10Godin B, Touitou E, Rubinstein E, et al. A new approach for treatment of deep skin infections by an ethosomal anti- biotic preparation: an in vivo study[J]. J Antimicrob Che- mother, 2005,55(6) : 989.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部